RANDOM MULTIPLE DOSE PLACEBO-CONTROLLED STUDY OF ARI-509 IN DIABETIC PATIENTS

本研究的目的是评估该药的临床安全性和安全性。 新型醛糖还原酶抑制剂ARI-509对糖尿病患者的耐受性 患者；评价ARI-509在多次给药后的药代动力学 通过测定血浆、红细胞和腓肠神经浓度 对ARI-509进行初步药效学评价 山梨醇、果糖和葡萄糖水平的连续测量。

The objective of this study is to assess the clinical safety and tolerance of ARI-509, a new aldose reductase inhibitor, in diabetic patients; to assess the pharmacokinetics of ARI-509 after multiple doses by measuring the plasma, erythrocyte (RBC) and sural nerve concentrations of ARI-509; and to assess preliminary pharmacodynamics of ARI-509 by serial measurement of sorbitol, fructose and glucose levels.